PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Bond Life Sciences Center, University of Missouri, Columbia, MO, USA.\', \'Department of Chemistry, University of Missouri, Columbia, MO, USA.\', \'cDepartment of Biochemistry, University of Missouri, Columbia, MO, USA.\', \'dDepartment of Veterinary Pathobiology, University of Missouri, Columbia, MO, USA.\', \'eDivision of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Huddinge, Stockholm, Sweden.\', \'fDepartment of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO, USA.\', \'Department of Veterinary Pathobiology, University of Missouri, Columbia, MO, USA.\', \'Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Huddinge, Stockholm, Sweden.\', \'gSanctum Therapeutics Corporation, Sunnyvale, CA, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1080/13543776.2021.1884224
?:doi
?:hasPublicationType
?:journal
  • Expert opinion on therapeutic patents
is ?:pmid of
?:pmid
?:pmid
  • 33593200
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.926
?:rankingScore_hIndex
  • 59
?:title
  • Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33593200>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33593200>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all